Lisa Bright B.Sc. — President of International at Intercept Pharmaceuticals

Ms. Lisa Bright, B.Sc., has been the President of International at Intercept Pharmaceuticals, Inc. since July 11, 2016. Ms. Bright served as the Chief Commercial and Corporate Affairs Officer at Intercept Pharmaceuticals, Inc. from February 2015 to July 11, 2016 and as its Senior Vice President since November 17, 2014 and Head of EUCA from November 2014 to February 2015. She is a Member of the Intercept Senior Management Team and spearheads Intercept's European operations based in London. She is a seasoned Executive with more than 25 years of biotech and pharmaceutical industry experience. From 2008 to November 2014, she held various leadership positions at Gilead Sciences Ltd., a biopharmaceutical company, including Vice President of Northern Europe and Vice President, Head of Sovaldi/HCV Launch Planning for Europe, Asia, Middle East and Australasia and Vice President, Head of Government Affairs for Europe, Middle East and Australasia. She joined Gilead as General Manager of UK & Ireland in 2008. Her leadership of Sovaldi's European launch contributed to the most successful product launch in pharmaceutical history. Prior to Gilead Sciences, she served in various positions of increasing responsibility at GlaxoSmithKline plc from 1997 to 2006 including Managing Director of GSK's New Zealand, Vice President of Commercial Planning and Operations, Global Vice President, General Manager of NZ and Head of Sales, UK and Ireland. She also worked at Sanofi from 1992 to 1996 and GlaxoSmithKline from 1989 to 1992. She serves as a Director of Ascendis Pharma A/S. Ms. Bright received her B.Sc. in Pharmacology from University College London, United Kingdom.